

DON'T MISS A **DIAGNOSIS.**

Syndromic BIOFIRE® Panels offer
faster time to result in ~1 hour.





Fast, accurate results for the right care, the first time.

BIOFIRE® Panels utilize a syndromic approach—simultaneously testing for a wide array of pathogens that can cause similar symptoms—for actionable results in about an hour. This can make a big difference in critical care, where the right information can lead to faster, more informed treatment.

7 Panels. 175+ Targets. ~1 Hour.



**BIOFIRE®
RESPIRATORY 2.1 PLUS PANEL†**
23 Targets. ~45 Minutes.



**BIOFIRE®
BLOOD CULTURE IDENTIFICATION 2 PANEL*†**
43 Targets. ~1 Hour.



**BIOFIRE® FILMARRAY®
GASTROINTESTINAL PANEL*†**
22 Targets. ~1 Hour.



**BIOFIRE® FILMARRAY®
MENINGITIS/ENCEPHALITIS PANEL*†**
14 Targets. ~1 Hour.



**BIOFIRE® FILMARRAY®
PNEUMONIA PLUS PANEL†**
34 Targets. ~1 Hour.



**BIOFIRE®
JOINT INFECTION PANEL*†**
39 Targets. ~1 Hour.



**BIOFIRE® FILMARRAY®
TROPICAL FEVER PANEL*†**
6 Targets. ~50 Minutes.

* FDA cleared

† CE 2797

Reduce time to results.

BIOFIRE® Panels may significantly reduce the time to actionable results compared to conventional test methods in critical situations.

BIOFIRE® RESPIRATORY 2.1 *PLUS* PANEL

7.7 hrs

standard-of-care
turnaround time for
influenza viruses¹

13.5 hrs

standard-of-care
turnaround time for
non-influenza viruses¹

vs

1.7 hrs

BIOFIRE RP2.1*plus* Panel
turnaround time for
influenza viruses¹

1.5 hrs

BIOFIRE RP2.1*plus* Panel
turnaround time for
non-influenza viruses¹

BIOFIRE® BLOOD CULTURE IDENTIFICATION 2 PANEL



51 hrs

faster turnaround time than culture
for ICU patients with suspected sepsis²



63 hrs

faster for advising on infection
prevention and control measures^{2*}

BIOFIRE® FILMARRAY® GASTROINTESTINAL PANEL



71.4 hrs

standard-of-care turnaround time³


vs



23.4 hrs

BIOFIRE FILMARRAY GI Panel turnaround
time for patients with HIV infection^{3†}

BIOFIRE® FILMARRAY® MENINGITIS/ENCEPHALITIS PANEL



137.3 hrs

standard-of-care median
time to therapy⁴


vs



3 hrs

BIOFIRE FILMARRAY ME Panel
median time to therapy⁴

BIOFIRE® FILMARRAY® PNEUMONIA *PLUS* PANEL



25 to 48 hrs

standard culture time
to deliver results⁵


vs



2.3 to 6.2 hrs

BIOFIRE FILMARRAY PN*plus* Panel
time to deliver results⁵

BIOFIRE® JOINT INFECTION PANEL



108 hrs

standard culture time
to deliver results⁶

vs



3.13 hrs

BIOFIRE JI Panel time to
deliver results⁶

*Data obtained with the previous version of the BIOFIRE BCID2 Panel.

†For patients with HIV infection.

Improve time to therapy and reduce empiric antibiotic use.



BIOFIRE® Panels may show a significant decrease in time to optimal therapy when combined with appropriate antimicrobial stewardship interventions.

BIOFIRE® RESPIRATORY 2.1 PLUS PANEL



19.1%

less likely to be prescribed empiric antibiotic therapy in hospitalized children less than 18 years old⁷



6.4 hrs

duration of empiric antibiotics vs. 32.9 hrs⁷

BIOFIRE® BLOOD CULTURE IDENTIFICATION 2 PANEL



39.1 hrs

faster time to optimal therapy with an established antimicrobial stewardship program^{8*}

BIOFIRE® FILMARRAY® GASTROINTESTINAL PANEL



Demonstrated to avoid unnecessary anti-infective therapy for patients with an HIV infection³

BIOFIRE® FILMARRAY® MENINGITIS/ENCEPHALITIS PANEL



39 hrs

In a systematic review, the BIOFIRE FILMARRAY ME Panel showed an average reduction in acyclovir use of 39 hours.⁹

BIOFIRE® FILMARRAY® PNEUMONIA PLUS PANEL



27.98 hrs

faster time to effective antibiotic administration compared to conventional culture¹⁰



17.5%

of ventilated immunocompromised ICU patients with acute respiratory failure received early modification of antibiotic therapy¹¹

BIOFIRE® JOINT INFECTION PANEL



28.9%

of patients received optimized antibiotic therapy due to increased diagnostic yield and decreased turnaround times¹²



66.4 hrs

reduction in time of empiric antibiotics¹³

*Data obtained with the previous version of the BIOFIRE BCID2 Panel.

Shorten patient stay in the ICU.

BIOFIRE® results may help inform patient management decisions, including optimizing therapy, discharging, or moving the patient into or out of isolation.


BIOFIRE® RESPIRATORY 2.1 PLUS PANEL



~1.35 days

reduction in length of stay in hospitalized patients¹⁴

BIOFIRE® FILMARRAY® GASTROINTESTINAL PANEL



17.5 days

length of stay using standard-of-care methods¹⁵

vs



7.5 days

length of stay using the BIOFIRE FILMARRAY GI Panel for hospitalized liver transplant recipients with diarrhea¹⁵

BIOFIRE® FILMARRAY® MENINGITIS/ENCEPHALITIS PANEL



1.5 day


mean reduction in ICU length of stay¹⁶



Reduce mortality.

BIOFIRE® results may lead to improved patient care and an increased survival rate of patients.

BIOFIRE® BLOOD CULTURE IDENTIFICATION 2 PANEL



Significant reduction in in-hospital and 30-day mortality among patients under 65 years old^{17*}

BIOFIRE® FILMARRAY® MENINGITIS/ENCEPHALITIS PANEL



Fast diagnosis of bacterial meningitis has been shown to reduce mortality¹⁸

BIOFIRE® FILMARRAY® PNEUMONIA *PLUS* PANEL



In patients with Ventilator-Associated Pneumonia (VAP), the use of the BIOFIRE FILMARRAY PN*plus* Panel was associated with a lower ICU mortality rate¹⁹

*Data obtained with the previous version of the BIOFIRE BCID2 Panel.

Improve economic impact.

The use of BIOFIRE® Panels may lead to reduced antibiotic use, reduced antibiotic duration, and shorter patient length of stay, which contribute to overall cost savings.

BIOFIRE® RESPIRATORY 2.1 PLUS PANEL



\$8,000
saved per adult ICU patient²⁰

BIOFIRE® BLOOD CULTURE IDENTIFICATION 2 PANEL



\$3,000
per patient in decreased overall hospital costs^{21*}

BIOFIRE® FILMARRAY® MENINGITIS/ENCEPHALITIS PANEL



\$12,240 USD
decrease per pediatric ICU patient
in private costs²²



\$2,916 USD
decrease per pediatric ICU patient
in public costs²²



\$2,319 CAD
case savings for ICU due to length
of stay reduction in adults¹⁶

BIOFIRE® FILMARRAY® PNEUMONIA PLUS PANEL



~19%
reduction in mean ICU costs for HAP/VAP in a UK-NHS context²³

*Data obtained with the previous version of the BIOFIRE BCID2 Panel.

Increase confidence with accurate results.

All BIOFIRE® Panels are either FDA cleared and/or CE marked. BIOFIRE technology is based on nested multiplex PCR results with high sensitivity and/or specificity.



BIOFIRE® RESPIRATORY 2.1 PLUS PANEL†

Overall Performance: 97.1% sensitivity, 99.3% specificity²⁴
SARS-CoV-2 Performance: 98.4% PPA, 98.9% NPA²⁵



BIOFIRE® BLOOD CULTURE IDENTIFICATION 2 PANEL*†

99.0% sensitivity, 99.7% specificity²⁶



BIOFIRE® FILMARRAY® GASTROINTESTINAL PANEL*†

98.7% sensitivity, 99.2% specificity²⁷



BIOFIRE® FILMARRAY® MENINGITIS/ENCEPHALITIS PANEL*†

94.2% sensitivity, 99.8% specificity²⁸



BIOFIRE® FILMARRAY® PNEUMONIA PLUS PANEL†

BAL-like: 96.2 % sensitivity, 98.3% specificity²⁹
Sputum-like: 96.3% sensitivity, 97.4% specificity²⁹



BIOFIRE® JOINT INFECTION PANEL*†

91.7% sensitivity, 99.8% specificity³⁰



BIOFIRE® FILMARRAY® TROPICAL FEVER PANEL*†

95.1% sensitivity, 99.8% specificity^{31,32}



* FDA cleared

† CE₂₇₉₇

Introducing the BIOFIRE® FILMARRAY® Tropical Fever (TF) Panel, the latest syndromic panel from bioMérieux.

Malaria, chikungunya, dengue and leptospirosis affect 100+ countries and are estimated to cause more than 300 million infections per year resulting in more than 600,000 deaths.³³⁻³⁶

These tropical fever infections often present with overlapping, non-specific signs and symptoms, making them challenging to diagnose. Their prevalence is expected to rise around the world as the impact of global climate change leads to conditions favorable to the spread of these diseases.³⁷

Molecular syndromic testing with the BIOFIRE FILMARRAY TF Panel cuts through diagnostic complexities by simultaneously testing 6 targets in about 50 minutes using a single test to provide answers in a clinically actionable timeframe. This may enable faster time to effective therapy and a reduction in unnecessary treatment.



**BIOFIRE® FILMARRAY®
TROPICAL FEVER
PANEL**

BIOFIRE syndromic testing can improve critical care.

BIOFIRE Panels can make a significant impact on ICU patient care. Syndromic testing provides fast, accurate, and reliable results for better patient management and outcomes in critical situations.



**ADD THE BIOFIRE PANELS TO YOUR
CRITICAL CARE WORKFLOW TODAY.**



References



1. Rappo U, *et al.* (2016) J. Clin. Microbiol. JCM.00549-16.
2. Rule R, *et al.* (2021) PLoS One. 16(7).
3. Sobczyk J, *et al.* (2020) Open Forum Infect Dis. 6;7(1).
4. Ordonez-Diaz KM, *et al.* (2020) Epidemiol. Infect. 148:e173:1-6.
5. Moy, A. C., *et al.* (2023). Anaesth Crit Care Pain Med: 101300.
6. Ghirardelli S. *et al.* J. Exp. Orthop., July 2024; 11(3):e12097
7. Lee BR, *et al.* J Clin Virol. 2019;110:11-16.
8. Chiasson J, *et al.* (2022) J Pharm Pract. 35(5):722-729.
9. Cailleaux M, *et al.* (2020) Eur.J.Clin.Microbiol.Infect. Dis.39:293-297.
10. de Albuquerque Pessoa Dos Santos, Y., *et al.* (2025). Crit Care, 29: 379
11. Contier, J. (2025) Crit Care, 29: 310.
12. Berinson *et al.* Microbiol Spectr, 2025; 13(4):e0223924
13. Lin TL, *et al.* (2025) Microbiol Spectr. 13:e00286-25
14. Kitano, Taito, *et al.* J Infect Chemother. 2020;26(1):82-85. doi:10.1016/j.jiac.2019.07.014.
15. Ching C, *et al.* (2022) Transpl Infect Dis. 24(4).
16. Didiodato G, *et al.* Open Forum Infect Dis.(2019)5:6(4).
17. Britt N, *et al.* (2022) Pharmacotherapy. doi: 10.1002/phar.2747.
18. Bodilsen J, *et al.* (2018) Clin Microbiol Infect.24(2):166.1
19. Rodríguez, A. *et al.* (2025) Biomedicines, 13.
20. Poelman *et al.* Future Microbiology. 2020 May; 15(8): 623–632
21. Pardo J, *et al.* (2016) Diagn Microbiol Infect Dis. 84(2):159.
22. Acuna M, *et al.* (2022)22:182.
23. Wagner, A. P. *et al.* (2025) Crit Care, 29: 352
24. Overall performance based on prospective clinical study for the BIOFIRE® Respiratory 2 *plus* Panel, data on file, BioFire Diagnostics
25. Overall performance based on prospective SARS-CoV-2 clinical study for the BIOFIRE® Respiratory 2.1 *plus* Panel in comparison to 3 EUA tests, data on file, BioFire Diagnostics.
26. Overall performance is the aggregate of the prospective, archived, and seeded data from the clinical studies.Data on file, BioFire Diagnostics.
27. Overall performance based on prospective clinical study for the BIOFIRE® FILMARRAY® Gastrointestinal Panel, data on file, BioFire Diagnostics.
28. Overall performance based on prospective clinical study for the BIOFIRE® FILMARRAY® Meningitis/Encephalitis Panel, data on file, BioFire Diagnostics.
29. Overall performance based on prospective clinical study for the BIOFIRE® FILMARRAY® Pneumonia *plus* Panel, data on file, BioFire Diagnostics.
30. Overall performance based on prospective clinical study for the BIOFIRE® Joint Infection Panel, data on file, BioFire Diagnostics.
31. Manabe Y, Betz J, Jackson O, Asoala V, Bazan I, Blair P, *et al.* Clinical evaluation of the BioFire Global Fever Panel for the identification of malaria, leptospirosis, chikungunya, and dengue from whole blood: a prospective, multicentre, cross-sectional diagnostic accuracy study. Lancet Infect Dis. 2022;22(9):1356–1364.
32. Performance claims are based on DEN200043 (De Novo) Global Fever Panel Clinical Studies (on file at bioMérieux).
33. World Health Organization. World Malaria Report 2024.
34. Bhatt S, Gething P, Brady O, Messina J, Farlow A, Moyes C, *et al.* The global distribution and burden of dengue. Nature. 2013;496(7446): 504–507.
35. Costa M, Hagan J, Calcagno J, Kane M, Torgerson P, Matinez-Silveira M, *et al.* Global Morbidity and Mortality of Leptospirosis: A Systematic Review. PLoS Negl Trop Dis. 2015;9(9):e0003898.
36. de Souza W, Ribeiro G, de Lima S, de Jesus R, Moreira F, Whittaker C, *et al.* Chikungunya: a decade of burden in the Americas. Lancet Reg Health Am. 2024;30:100673.
37. Liao H, Lyon C, Ying B, Hu T. Climate change, its impact on emerging infectious diseases and new technologies to combat the challenge. Emerg Microbes Infect. 2024;13(1): 2356143.



“Getting an answer within an hour is something that’s very powerful to clinicians: it gives us actionable information right away.”

- Tufik Assad, MD, MSCI
Pulmonary and Critical Care Physician.*

* Dr. Assad is a paid consultant of bioMérieux, Inc.



Contact Us

bioMérieux S.A.
69280 Marcy l'Etoile
France
Tel: +33 (0) 4 78 87 20 00
biomerieux.com

Manufactured by:
BIOFIRE Diagnostics, LLC
515 Colorow Drive
Salt Lake City, UT 84108 USA
Tel: +1-801-736-6354

Product availability varies by country. Please contact your local bioMérieux representative for details.

Learn more: biomerieux.com

PIONEERING DIAGNOSTICS